These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10969976)

  • 1. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1.
    Jeong HW; Kim MR; Son KH; Han MY; Ha JH; Garnier M; Meijer L; Kwon BM
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1819-22. PubMed ID: 10969976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
    Zhu G; Conner S; Zhou X; Shih C; Brooks HB; Considine E; Dempsey JA; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1231-5. PubMed ID: 12657252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of novel inhibitors of cyclin-dependent kinases.
    Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
    Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
    Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity.
    Reynaud EG; Guillier M; Leibovitch MP; Leibovitch SA
    Oncogene; 2000 Feb; 19(9):1147-52. PubMed ID: 10713702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
    Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
    J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
    Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
    J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
    Sanchez-Martinez C; Shih C; Faul MM; Zhu G; Paal M; Somoza C; Li T; Kumrich CA; Winneroski LL; Xun Z; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Considine E; Dempsey JA; Ogg CA; Campbell RM; Anderson BA; Wagner J
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3835-9. PubMed ID: 14552791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
    Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
    J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
    García MD; Wilson AJ; Emmerson DP; Jenkins PR; Mahale S; Chaudhuri B
    Org Biomol Chem; 2006 Dec; 4(24):4478-84. PubMed ID: 17268643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
    Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
    Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A.
    Kim DM; Yang K; Yang BS
    Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of selective inhibitors of cyclin dependent kinase 4.
    Carini DJ; Kaltenbach RF; Liu J; Benfield PA; Boylan J; Boisclair M; Brizuela L; Burton CR; Cox S; Grafstrom R; Harrison BA; Harrison K; Akamike E; Markwalder JA; Nakano Y; Seitz SP; Sharp DM; Trainor GL; Sielecki TM
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2209-11. PubMed ID: 11514172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
    Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).
    Cheng M; Sexl V; Sherr CJ; Roussel MF
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1091-6. PubMed ID: 9448290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.